These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34245333)

  • 1. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
    Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
    Hong CR; Bogle G; Wang J; Patel K; Pruijn FB; Wilson WR; Hicks KO
    Front Pharmacol; 2018; 9():1013. PubMed ID: 30279659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
    Foehrenbacher A; Patel K; Abbattista MR; Guise CP; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013; 3():263. PubMed ID: 24109591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
    Wong WW; Jackson RK; Liew LP; Dickson BD; Cheng GJ; Lipert B; Gu Y; Hunter FW; Wilson WR; Hay MP
    Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
    Jackson-Patel V; Liu E; Bull MR; Ashoorzadeh A; Bogle G; Wolfram A; Hicks KO; Smaill JB; Patterson AV
    Front Pharmacol; 2022; 13():803602. PubMed ID: 35211015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
    Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
    Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
    Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
    Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
    Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
    J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
    Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
    Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
    Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids.
    Mao X; McManaway S; Jaiswal JK; Patel PB; Wilson WR; Hicks KO; Bogle G
    PLoS Comput Biol; 2018 Oct; 14(10):e1006469. PubMed ID: 30356233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
    Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
    Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
    Guise CP; Abbattista MR; Anderson RF; Li D; Taghipouran R; Tsai A; Lee SJ; Smaill JB; Denny WA; Hay MP; Wilson WR; Hicks KO; Patterson AV
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33105798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering the
    Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
    Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.